IPO Fri­day: Hy­per­ten­sion drug­mak­er Min­eralys maps out $192M Nas­daq de­but

Wall Street is wel­com­ing a new drug de­vel­op­er to the stock mar­kets for the sec­ond Fri­day in a row.

Min­eralys Ther­a­peu­tics said Thurs­day night its ini­tial pub­lic of­fer­ing had priced at $16 per share, the high end of its pro­posed range, with an ex­pect­ed $192 mil­lion in pro­ceeds.

The biotech, near­ing a Phase III for its lead as­set, joins a small club of drug de­vel­op­ers that has jumped on­to the pub­lic mar­kets re­cent­ly af­ter the IPO door ap­peared to slam shut last win­ter.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.